The most G protein-selective μ-opioid receptor agonist in the published literature. Seven peer-reviewed papers. Two salt forms. One standard of purity.
SR-17018 (CAS 2134602-45-0) is a functionally selective agonist of the μ-opioid receptor that preferentially activates G protein signalling over β-arrestin-2 recruitment. First described by Schmid et al. in Cell (2017), it has become one of the most studied biased agonists in opioid pharmacology.
The biased agonism hypothesis predicts that separating G protein activation from β-arrestin-2 recruitment could yield analgesic efficacy with reduced tolerance, respiratory depression, and withdrawal. SR-17018's bias factor of 80-100x (vs DAMGO) makes it the sharpest tool available to test this hypothesis.
Preclinical data show reduced tolerance in chronic dosing, reversal of established morphine tolerance, and suppression of withdrawal signs in rodent models.
The unprotonated form. Ideal for in vitro assays where precise molar concentrations are required.
Enhanced aqueous solubility for formulation-sensitive applications. Faster dissolution in acidic media.
Every lot tested: NMR, MS, HPLC, TLC, Karl Fischer, ICP-MS, USP 61/62
Discreet packaging, research-use documentation, customs-ready declarations
Bitcoin via BTCPay Server (self-hosted) and SEPA bank transfer accepted
Full pharmacology review with original figures and all 7 citations
The two-pathway model, cAMP rebound, and why β-arrestin-2 matters.
Freebase vs HCl, the dissolution bottleneck, and formulation strategies.